Alnylam Pharmaceuticals reported $7.82M in Interest Income for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Interest Income Change
Acadia Pharmaceuticals ACAD:US USD 2.3M 1.72M
Alnylam Pharmaceuticals ALNY:US USD 7.82M 5.92M
Arrowhead Research ARWR:US USD 1.58M 343K
Avrobio Inc AVRO:US USD 111K 396K
BioCryst Pharmaceuticals BCRX:US USD 1.76M 1.15M
BioMarin Pharmaceutical BMRN:US USD 5M 2.49M
Bluebird Bio BLUE:US USD 383K 209K
Moderna Inc MRNA:US USD 58M 18M
Regulus Therapeutics RGLS:US USD 187K 108K
Sangamo BioSciences SGMO:US USD 1.77M 874K
Sarepta Therapeutics SRPT:US USD 4.78M 2.37M
Ultragenyx Pharmaceutical RARE:US USD 3.48M 2.58M
Vertex Pharmaceuticals VRTX:US USD 46.2M 35.4M
Xencor XNCR:US USD 1.38M 662K